Page last updated: 2024-09-03

gefitinib and Chronic Hepatitis C

gefitinib has been researched along with Chronic Hepatitis C in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ	1
Hanajiri, K; Maruyama, T; Mitsui, H; Nakajima, J; Omata, M	1

Other Studies

2 other study(ies) available for gefitinib and Chronic Hepatitis C

Article	Year
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. The oncologist, 2017, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan	2017
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines	2003

Article

Year

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

The oncologist, 2017, Volume: 22, Issue:9

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan

2017

Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.

Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373

Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines

2003